Clinical Trial: Impact of Rosuvastatin Doses on LDL Levels, CPK Levels and Aspartate Aminotransferase Levels

U.S., April 5 -- ClinicalTrials.gov registry received information related to the study (NCT06910098) titled 'Impact of Rosuvastatin Doses on LDL Levels, CPK Levels and Aspartate Aminotransferase Levels' on March 22.

Brief Summary: Particpants were divided into groups based on doses of rosuvastatin and were assessed and for CPK, LDL and AST levels

Study Start Date: Dec. 01, 2023

Study Type: INTERVENTIONAL

Condition: LDL - Low Density Lipoprotein Receptor Disorder Rosuvastatin

Intervention: DRUG: Rosuvastatin

a dose of 5mg were given and were compared for the cpk, ast and ldl levels

DRUG: Rosuvastatin

a dose of 10 mg were given and were compared for the cpk, ast and ldl levels

DRUG: Rosuvastatin

a dose of 20 mg were given and were...